Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GlaxoSmithKline
Age
18–70
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subject able to understand and voluntarily provide the consent to participate in the study
18 - 70 years of age, inclusive, at the time of signing the informed consent and Body Mass Index (BMI) between 18.0 and 35.0 Kilogram (kg) per m\^2, inclusive
Understands and is willing, able and likely to be compliant with taking study drug and comply with all study procedures and restrictions
Subject is willing to consume the foods that are part of the standardized breakfast, lunch, and dinner
In good general health with no clinically significant and relevant abnormalities of medical history or physical examination which includes adequate renal function, alanine transaminase (ALT), alkaline phosphatase and bilirubin \<=1.5x Upper Limit of Normal (ULN )
QTcF \< 450 millisecond (msec); or QTcF \< 480msec for subjects with right Bundle Branch Block
Females must be post-menopausal
Females on hormone replacement therapy (HRT) must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment
Females who are \> 3 months postpartum and who have undergone a surgical sterilization procedure are eligible to participate in consultation with the GSK Medical Monitor
Parts B and C (Type 2 Diabetic Subjects)
All the criteria mentioned in Part A except Body Mass Index (BMI) should be between 30.0 and 42.0 kg per m\^2
Diagnosis of T2D for at least 3 months, as defined by the American Diabetes Association
All T2D subjects must meet label recommendations for metformin
For Part B, subjects must be willing to discontinue metformin and replace it with daily liraglutide administered by subcutaneous injection and they must meet label recommendations
No personal history or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
You may not be if
History of gastrointestinal disease, current or chronic history of liver disease, history of serious, severe or unstable physical or psychiatric illness , significant cardiovascular disease, surgery for weight loss or gastrointestinal surgery within 3 months of screening, any documented or reported eating disorder, uncontrolled hypertension, as evidenced by systolic pressure\>160 or diastolic pressure \>90 mmHg
Positive test for HIV, Hepatitis B, or Hepatitis C at Screening
Subjects with significant ECG abnormalities
For subjects in Part C (continuing metformin), history of untreated pernicious anemia or who have laboratory parameters suggestive of subclinical megaloblastic anemia
Presence of or symptoms of an active infection
Uncorrected Thyroid Dysfunction
History of chronic or acute pancreatitis
Currently dieting to lose weight including, but not limited to, participation in a program designed to alter body weight within the last 60 days and unwilling to maintain relatively consistent exercise patterns throughout the study
Current or recent history (within one year of screening) of alcohol or other substance abuse
Unable to refrain from the use of non-prescription drugs
Current participation in another clinical study or participation in a clinical study involving an investigational drug within 30 days of the screening visit
History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy
An employee of the sponsor or the study site or members of their immediate family.
